←Back to Expert Scholars
Translational Medicine / 转化医学Emerging Lung Targets
Justin Gainor
MD
🏢Massachusetts General Hospital🌐USA
Director, Center for Thoracic Cancers
60
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Justin Gainor directs MGH's thoracic cancer center, leading first-in-human trials of ADC and bispecific therapies. His work on tusamitamab ravtansine (CEACAM5) and next-generation ALK drugs has shaped the emerging targets landscape. He also studies tumor immune microenvironment features driving treatment response.
Share:
🧪Research Fields 研究领域
ALK inhibitors
Immunotherapy combinations
Resistance biology
CEACAM5
Early-phase trials
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Justin Gainor 的研究动态
Follow Justin Gainor's research updates
留下邮箱，当我们发布与 Justin Gainor（Massachusetts General Hospital）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment